Clinical Trials Logo

Clinical Trial Summary

Uptake, adherence, and completion of vaccination among drug users were low, and their immune function and immune response to hepatitis B vaccination were also suboptimal, indicating that the current practice of hepatitis B vaccination can't protect drug users from HBV infection. This is a randomized, open-label, blank-controlled trial, conducted among drug users with drug rehabilitation. This study will compare the immunogenicity and safety of three intramuscular 20µg and 60µg recombinant hepatitis B vaccines at months 0, 1, and 6 among drug users


Clinical Trial Description

Comparison of 2 vaccination strategy against Hepatitis B in Drug Users Intervention: Arm 1 : Receive three intramuscular injections of 60 µg recombinant hepatitis B vaccine at months 0, 1 and 6; Arm 2 : Receive three intramuscular injections of 20 µg recombinant hepatitis B vaccine at months 0, 1 and 6; Arm 3 : Receive no vaccination during the study period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02959775
Study type Interventional
Source Shanxi Medical University
Contact
Status Completed
Phase Phase 4
Start date August 2014
Completion date October 2015

See also
  Status Clinical Trial Phase
Recruiting NCT05787899 - Hypothermia's Effect on Hepatitis B Vaccination
Completed NCT04162223 - Hepatitis B Vaccine in Seniors Early Phase 1
Terminated NCT02166671 - Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years N/A